☆ 4.6 Review

Non-invasive plasma testing for CD274 UTR structural variations by next-generation sequencing in cancer

CELL DEATH DISCOVERY (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors

Marzia Del Re et al.

Summary: Monoclonal antibodies targeting the PD-1/PD-L1 axis enhance immune response to cancer, but some patients do not benefit from treatment due to resistance or adverse reactions. Currently, PD-L1 expression in tumor tissues is used to predict drug response, but researchers are interested in identifying blood-based biomarkers for dynamic monitoring of response.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Review Oncology

Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors

Zhu Zeng et al.

Summary: Immunotherapy has shown promising efficacy in digestive system tumors, but identifying responders and non-responders remains a challenge. PD-L1 expression, though a potential biomarker, is not sufficient for differentiation. Other molecules like TMB, MSI, and ctDNA are being explored for their predictive value in immunotherapy outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients

Guanghui Gao et al.

Summary: This study analyzed 16,013 samples from Chinese cancer patients and found that amplification of CD274 varied in different cancer types and was associated with TMB, MSI, and PD-L1 expression. The role of CD274 amplification as a novel biomarker of PD-1/PD-L1 inhibitors needs further characterization in future prospective clinical studies.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Oncology

Current strategies for intratumoural immunotherapy-Beyond immune checkpoint inhibition

Jianda Yuan et al.

Summary: Immunotherapy has significantly improved cancer treatment by activating host antitumor immune responses, with immune checkpoint inhibitors showing durable responses in some patients. Ongoing clinical research is focused on understanding mechanisms of ICI resistance to enhance response rates and overall survival, and evaluating novel combination therapies to overcome resistance in the tumor microenvironment.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors

Ho Jung An et al.

Summary: Recent advances in high-throughput multiplexed analytical technologies have identified various peripheral blood-based immune biomarkers that can be crucial for selecting cancer patients suitable for ICIs treatment. The identification of these biomarkers helps overcome the limitations of previously used tissue-based biomarkers and offers non-invasive and repeatable methods for detection from blood samples.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Ye Wang et al.

Summary: The response to immune checkpoint inhibitors is a complex quantitative trait determined by multiple factors, for which FDA-approved biomarkers are used for patient selection. However, challenges in daily practice and the different factors captured by the biomarkers highlight the need for optimized use of current biomarkers and development of new predictive biomarkers. Various gene signature biomarkers and combined predictive biomarkers have shown improved performance compared to single predictors, suggesting a potential direction for robust predictive biomarker development for ICI response.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma

Jiansheng Huang et al.

FEBS OPEN BIO (2020)

Add to Collection

Letter Oncology

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Jing Quan Lim et al.

LEUKEMIA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA

Yu Wu et al.

BIOCHEMICAL JOURNAL (2020)

Add to Collection

Article Oncology

eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer

Shruthy Suresh et al.

NATURE CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Shunli Peng et al.

MOLECULAR CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer

Yanhua Wu et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Article Oncology

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

Stefania Bellone et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Adrien Costantini et al.

ONCOIMMUNOLOGY (2018)

Add to Collection

Article Oncology

Variant SNPs at the microRNA complementary site in the B7-H1 3'-untranslated region increase the risk of non-small cell lung cancer

Wenwen Du et al.

MOLECULAR MEDICINE REPORTS (2017)

Add to Collection

Article Multidisciplinary Sciences

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Keisuke Kataoka et al.

NATURE (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.